Zymogenetics, Inc.

Bristol-myers Squibb Compnay

Five Prime Therapeutics, Inc.

Other

American Cyanamid Company

Novo Nordisk A/s

Paul O Sheppard

Kevin M Klucher

Thomas R Bukowski

Brian A Fox

Dennis L Dong

Lowell J Brady

Chung Chan

Hong Yan Liu

Paul D Bishop

Theresa A Deisher

Wayne R Kindsvogel

Francis J Grant

Teresa Gilbert

Scott R Presnell

Charles E Hart

David W Taft

Betty A Haldeman

Stephen R Jaspers

Guodong Chen

Christopher S Piddington

Alan J Korman

Zeren Gao

Darrell C Conklin

Brigitte Devaux

Debra G Gilbertson

Daniel F Ardourel

Nand Baindur

Ekaterina G Deyanova

Kimberly E Shoemaker

Andy X Deng

Mohan Srinivasan

Richard Y Huang

Indrani Chakraborty

Fenella C Raymond

Mark J Selby

James William West

Arvind Rajpal

Michelle Minhua Han

Huiming Li

Patrick J O'Hara

Xiao Min Schebye

Christine Bee

Susan D Holderman

Robert J Johnston

Andrew Rankin

Laura J Jelinek

Anan Chuntharapai

David A Adler

Ginger Chao Rakestraw

Si Lok

Mark F Maurer

Emma E Moore

James L Holloway

Rolf E Kuestner

Keith Sadoon Bahjat

Michelle Renee Kuhne

Lin Hui Su

Luis Borges

Hong-An Truong

Birgit Hansen

Donald C Foster

Hong Liu

Joseph Leon Kuijper

Josephine M Cardarelli

Mark W Rixon

Stanley Richard Krystek, Jr

Alison Witte

Virender M Labroo

Brenda L Stevens

Penny Thompson

Susan Wong

Thomas D Kempe

Tseng-hui Timothy Chen

Hui Wei

Lumelle A Schneeweis

Xiaodi Deng

Chung-Leung Chan

Susan H Julien

Stephanie Beigel-Orme

Jeff Lynn Ellsworth

Robert R West

Andrzej Z Sledziewski

Gerald W Lasser

Angelika Grossmann

Edward C Thayer

Julia E Novak

Stacey R Dillon

Pavel Strop

Chetana Rao-Naik

Akbar Nayeem

Steven Sheriff

Jacqueline M Humes

Jason Robert Pinckney

Katherine E Lewis

Michael Quigley

Richard Yu-Cheng Huang

Theresa M Farrah

Richard M Garcia

William Hagopian

Tracey A Pownder

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.

Antibodies against TIM3 and uses thereof

An antibody has a glutamine-containing extension at the C-terminus of a light chain thereof, making it suitable for conjugation via transglutaminase-mediated transamidation.

Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses

The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.

Antibodies binding to VISTA at acidic pH

Antibodies binding to vista at acidic pH

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.

The present invention provides antibodies, or antigen binding fragments thereof, that bind to human TIGIT (T cell immunoreceptor with Ig and ITIM domains), as well as uses of these antibodies or fragments in therapeutic applications, such as in the treatment of cancer or chronic viral infection. Such method of treatment include combination therapy with inhibitors of other immunomodulatory receptor interactions, such as the PD-1/PD-L1 interaction. The invention further provides polynucleotides encoding the heavy and/or light chain variable region of the antibodies, expression vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies, cells comprising the vectors, and methods of making the antibodies or fragments by expressing them from the cells.

Antibodies to TIGIT

Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.

Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.

Methods of treating inflammation with IL-17A/F and IL-23P19 bispecific antibodies

Growing community of inventors

Granite Falls, WA, United States of America

Paul O Sheppard